News | Published:

Death by inflammation: drug makers chase the master controller

Nature Biotechnologyvolume 37pages111113 (2019) | Download Citation

Subjects

Companies are now looking at RIPK1 inhibitors for diseases like neurodegeneration and even cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

  1. Dublin, Ireland

    • Cormac Sheridan

Authors

  1. Search for Cormac Sheridan in:

Corresponding author

Correspondence to Cormac Sheridan.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41587-019-0023-4

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing